Rallybio to Effect 1-for-8 Reverse Stock Split
Rallybio Corporation will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybio's Amended and Restated Certificate of Incorporation (the "Amendment") to effect the reverse stock split at a Special Meeting of Stockholders held on January 26, 2026. The reverse stock split is intended to give Rallybio greater flexibility in considering and planning for future potential business needs and to increase the per share trading price of the Rallybio common stock to enable Rallybio to satisfy the minimum price requirement for continued listing on the Nasdaq Capital Market. Pursuant to the Amendment, the reverse stock split will be effective at 12:01 a.m., Eastern Time, on February 6, 2026. Rallybio expects that upon the opening of trading on February 6, 2026, its common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the current trading symbol "RLYB" and the new CUSIP number 75120L 209.
Trade with 70% Backtested Accuracy
Analyst Views on RLYB
About RLYB
About the author
Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours
InflaRx N.V. Surge: InflaRx N.V. saw a significant after-hours increase of 63.41% to $2.01, driven by the anticipation of topline data from its Phase 2a trial and third-quarter financial results expected on Monday.
Rallybio Corp. Performance: Rallybio Corp. rose 12.84% to $0.71 after reporting a third-quarter net income of $16.0 million, reversing a loss from the previous year, although revenue slightly declined.
FibroBiologics Inc. Growth: FibroBiologics Inc. climbed 13.51% to $0.40 after hours, following a previous corporate update and third-quarter financial results released on October 31.
Cellectis S.A. Recovery: Cellectis S.A. increased by 6.58% to $3.40 after reporting a third-quarter net income of $589 thousand, a significant improvement from a loss in the prior year, with revenues more than doubling.
Rallybio Announces Financial Results for Q3 2025 and Shares Business Developments
RLYB116 Study Progress: Rallybio has completed dosing for Cohort 1 in the RLYB116 Phase 1 confirmatory PK/PD study, with data expected in Q4 2025, targeting immune platelet transfusion refractoriness and refractory antiphospholipid syndrome.
Financial Highlights: The company generated $20 million from the sale of its interest in REV102, extending its cash runway through 2027, and reported a net income of $16 million for Q3 2025, a significant improvement from a net loss in the same period last year.
Post-Market Activity: Biotech and Medtech Stocks Surge on Increased Volume and Announcements
Biotech Stock Movements: Several biotech and medical device stocks experienced significant after-hours gains, with Reviva Pharmaceuticals (RVPH) leading the surge with an 18.27% increase, driven by high trading volume and recent catalysts related to its lead candidate brilaroxazine.
Company Updates and Guidance: Penumbra Inc. (PEN) and Palisade Bio Inc. (PALI) also saw notable increases, with PEN benefiting from executive changes and positive revenue guidance, while PALI's rise was linked to a successful public offering and clinical updates.
Rallybio Finishes Dosing Initial Group in Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study for RLYB116
RLYB116 Study Progress: Rallybio Corporation has completed dosing for the first cohort in a Phase 1 study of RLYB116, a C5 inhibitor, showing promising pharmacokinetic and pharmacodynamic results, along with a favorable safety profile.
Future Plans and Market Potential: The company plans to escalate dosing to a second cohort and aims to target two hematologic conditions, immune platelet transfusion refractoriness and refractory antiphospholipid syndrome, which present a combined market opportunity of $5 billion.
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M
Rallybio's Agreement with Recursion Pharmaceuticals: Rallybio has agreed to sell its interest in the preclinical drug REV102 to Recursion Pharmaceuticals for up to $25 million, which includes an upfront payment of $7.5 million and potential milestone payments.
Financial Impact on Rallybio: The deal is expected to extend Rallybio's cash runway into mid-2027, and they will also receive royalties on future sales of REV102 by Recursion.
Why Is Microcap Rallybio Stock Trading Higher On Tuesday?
Rallybio Corporation's Sale of REV102: Rallybio has agreed to sell its interest in the ENPP1 inhibitor REV102 to Recursion Pharmaceuticals for up to $25 million, which includes an upfront payment of $7.5 million, extending Rallybio's cash runway into mid-2027.
Impact on Stock Prices: Following the announcement, Rallybio's stock rose by 36.8% to $0.47, while Recursion's stock increased by 0.81% to $4.97 during premarket trading.
Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours
InflaRx N.V. Surge: InflaRx N.V. saw a significant after-hours increase of 63.41% to $2.01, driven by the anticipation of topline data from its Phase 2a trial and third-quarter financial results expected on Monday.
Rallybio Corp. Performance: Rallybio Corp. rose 12.84% to $0.71 after reporting a third-quarter net income of $16.0 million, reversing a loss from the previous year, although revenue slightly declined.
FibroBiologics Inc. Growth: FibroBiologics Inc. climbed 13.51% to $0.40 after hours, following a previous corporate update and third-quarter financial results released on October 31.
Cellectis S.A. Recovery: Cellectis S.A. increased by 6.58% to $3.40 after reporting a third-quarter net income of $589 thousand, a significant improvement from a loss in the prior year, with revenues more than doubling.
Rallybio Announces Financial Results for Q3 2025 and Shares Business Developments
RLYB116 Study Progress: Rallybio has completed dosing for Cohort 1 in the RLYB116 Phase 1 confirmatory PK/PD study, with data expected in Q4 2025, targeting immune platelet transfusion refractoriness and refractory antiphospholipid syndrome.
Financial Highlights: The company generated $20 million from the sale of its interest in REV102, extending its cash runway through 2027, and reported a net income of $16 million for Q3 2025, a significant improvement from a net loss in the same period last year.
Post-Market Activity: Biotech and Medtech Stocks Surge on Increased Volume and Announcements
Biotech Stock Movements: Several biotech and medical device stocks experienced significant after-hours gains, with Reviva Pharmaceuticals (RVPH) leading the surge with an 18.27% increase, driven by high trading volume and recent catalysts related to its lead candidate brilaroxazine.
Company Updates and Guidance: Penumbra Inc. (PEN) and Palisade Bio Inc. (PALI) also saw notable increases, with PEN benefiting from executive changes and positive revenue guidance, while PALI's rise was linked to a successful public offering and clinical updates.
Rallybio Finishes Dosing Initial Group in Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study for RLYB116
RLYB116 Study Progress: Rallybio Corporation has completed dosing for the first cohort in a Phase 1 study of RLYB116, a C5 inhibitor, showing promising pharmacokinetic and pharmacodynamic results, along with a favorable safety profile.
Future Plans and Market Potential: The company plans to escalate dosing to a second cohort and aims to target two hematologic conditions, immune platelet transfusion refractoriness and refractory antiphospholipid syndrome, which present a combined market opportunity of $5 billion.
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M
Rallybio's Agreement with Recursion Pharmaceuticals: Rallybio has agreed to sell its interest in the preclinical drug REV102 to Recursion Pharmaceuticals for up to $25 million, which includes an upfront payment of $7.5 million and potential milestone payments.
Financial Impact on Rallybio: The deal is expected to extend Rallybio's cash runway into mid-2027, and they will also receive royalties on future sales of REV102 by Recursion.
Why Is Microcap Rallybio Stock Trading Higher On Tuesday?
Rallybio Corporation's Sale of REV102: Rallybio has agreed to sell its interest in the ENPP1 inhibitor REV102 to Recursion Pharmaceuticals for up to $25 million, which includes an upfront payment of $7.5 million, extending Rallybio's cash runway into mid-2027.
Impact on Stock Prices: Following the announcement, Rallybio's stock rose by 36.8% to $0.47, while Recursion's stock increased by 0.81% to $4.97 during premarket trading.
